{"id":28607,"date":"2023-04-18T15:15:24","date_gmt":"2023-04-18T19:15:24","guid":{"rendered":"https:\/\/www.cancerresearch.org\/?post_type=cri_news&p=28607"},"modified":"2023-04-18T15:35:24","modified_gmt":"2023-04-18T19:35:24","slug":"immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities","status":"publish","type":"cri_news","link":"https:\/\/www.cancerresearch.org\/es\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities","title":{"rendered":"Immunotherapy Drug Development Pipeline Shifts from Traditional Therapies to Newer Modalities"},"content":{"rendered":"\n

NEW YORK, NY, APRIL 18, 2023<\/p>\n\n\n\n

NEW YORK \u2013 After years of broad and rapid growth, immuno-oncology (IO) clinical trials seem to be shifting from the traditional heavyweights to new directions, according to the latest update of the global IO Landscape Analysis published in Nature Reviews Drug Discovery<\/em><\/a> by the Cancer Research Institute (CRI) Anna-Maria Kellen Clinical Accelerator.<\/p>\n\n\n\n

\u201cAs the field of IO matures and works to develop therapies that will be effective for all cancer patients, it is obvious that scientific innovation continues to drive clinical discovery,\u201d says CRI CEO and Director of Scientific Affairs Jill O\u2019Donnell-Tormey, PhD.<\/p>\n\n\n\n

Overall, while the number of new IO trials dropped for the first time since this analysis began in 2018, a record number of IO targets (195) are being investigated in clinical trials launched in 2022. Significant increases in new cell therapies, cancer vaccines, and other immunomodulators led to \u201chealthy signs of innovation\u201d that will hopefully lead to more cures for more patients.<\/p>\n\n\n\n

This latest analysis examined 9,007 IO trials that began between 2018 and 2022 and observed a 2.86% decrease in new trials in 2022 compared to 2021, driven by a 6.4% decrease in phase 2 trials. Conversely, the number of phase 1 and phase 3 trials increased by 8.8% and 6.6%, respectively. Among all trials, there was a 10.3% decrease in those using PD-1\/PD-L1 inhibitors, whereas other targets like CTLA-4, LAG-3, and CD3 T cell-engager increased 17.9%, 36.8%, and 13.3%, respectively.<\/p>\n\n\n\n

Cell therapy clinical trials increased across the board, especially with more novel approaches. Trials with the most established cell therapy technique \u2014 CAR T cells \u2014 increased 5.6%, compared to increases of 24.2% for other T cell therapies, 7.7% for natural killer cell therapies, and 28.6% for therapies involving bacteria.<\/p>\n\n\n\n

Immense investments were made in cell therapies for the treatment of solid cancers, which have proven elusive for current cell therapies. The hope is they can begin to approach the incredible effectiveness these treatments have achieved in blood cancers. In 2022, cell therapy trials in solid cancers accounted for 47% of all cell therapy trials, up 14.2% from the previous year.<\/p>\n\n\n\n

The scope of IO-based therapies also expanded, with the number of therapeutic targets expanding from 146 in 2020, to 160 in 2021, to 195 targets now in 2022. IO modalities with significant growth in trials included cancer vaccines (17.4%) and non-T cell immunomodulators (9.2%). For the latter, there was a prominent shift \u2014 10.4% compared to 2021 \u2014 away from antibody-based therapies. In contrast, trials with recombinant or fusion proteins, now the dominant modality among non-T cell immunomodulators, grew by 8% in 2022.<\/p>\n\n\n\n

\u201cThe changes we observe in our latest analysis of the IO landscape are very exciting for the IO field. We see that interrogation of novel targets and mechanisms of action keeps growing and that newer therapeutic modalities are gaining ground to anti-PD1\/PDL1 monoclonal antibodies,\u201d says the Nature Reviews Drug Discovery <\/em>article\u2019s first author, Ana Rosa S\u00e1ez Ib\u00e1\u00f1ez, PhD, research analyst for CRI\u2019s Clinical Accelerator and Venture Fund. \u201cThese newer agents, such as T-cell engagers, bispecific antibodies, and cell therapies in the solid tumor space, hold huge potentials. The fact that we observe an increase in research utilizing these modalities is good news for cancer patients.\u201d<\/p>\n\n\n\n

Related Link:<\/strong> View CRI\u2019s interactive dashboard reflecting the latest I-O Landscape data at cancerresearch.org\/IO-landscape<\/a><\/p>\n\n\n\n

Reference:<\/strong> S\u00e1ez Ib\u00e1\u00f1ez AR et al. Immuno-oncology clinical trials take a turn beyond PD1\/PDL1 inhibitors. Nat. Rev. Drug Discov.<\/em> 14 Apr 2023.<\/a><\/p>\n\n\n\n

Media Contact:<\/strong><\/p>\n\n\n\n

Sharon Slade, +1.212.688.7515 x230, sslade@cancerresearch.org<\/a><\/p>\n\n\n\n

About the Cancer Research Institute<\/strong><\/p>\n\n\n\n

The Cancer Research Institute (CRI), established in 1953, is a top-rated U.S. nonprofit organization dedicated exclusively to saving more lives by fueling the discovery and development of powerful immunotherapies for all cancers. Guided by a world-renowned Scientific Advisory Council that includes four Nobel laureates and 27 members of the National Academy of Sciences, CRI has invested $500 million in support of research conducted by immunologists and tumor immunologists at the world\u2019s leading medical centers and universities and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. To learn more, go to cancerresearch.org.<\/p>\n\n\n\n

About the Anna-Maria Kellen Clinical Accelerator<\/strong> The CRI Anna-Maria Kellen Clinical Accelerator is a unique nonprofit-academia-industry collaboration model that serves as an \u201cincubator\u201d for multi-center clinical trials testing promising new cancer immunotherapy combinations. As part of the CRI Trials umbrella of clinical programs, the Clinical Accelerator powers integrative, science-driven, collaborative clinical research platforms designed to facilitate and de-risk cancer immunotherapy drug development by leveraging the global CRI Network of immuno-oncology experts and CRI\u2019s philanthropic venture fund. To learn more about the Anna-Maria Kellen Clinical Accelerator, go to cancerresearch.org\/clinical-accelerator<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, NY, APRIL 18, 2023 NEW YORK \u2013 After years of broad and rapid growth, immuno-oncology (IO) clinical trials seem to be shifting from the traditional heavyweights to new directions, according […]<\/p>\n","protected":false},"featured_media":28608,"template":"","tags":[32,35],"resource_cancer_types":[],"resource_patient_age":[],"resource_cancer_stage":[],"resource_treatment_type":[],"resource_treatment_status":[],"class_list":["post-28607","cri_news","type-cri_news","status-publish","has-post-thumbnail","hentry","tag-clinical-trials","tag-combination-therapies"],"acf":[],"yoast_head":"\nImmunotherapy Drug Development Pipeline Shifts from Traditional Therapies to Newer Modalities - Cancer Research Institute<\/title>\n<meta name=\"description\" content=\"The cancer immunotherapy clinical trial landscape is shifting, with more focused sponsorship and hopes for further innovation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunotherapy Drug Development Pipeline Shifts from Traditional Therapies to Newer Modalities - Cancer Research Institute\" \/>\n<meta property=\"og:description\" content=\"The cancer immunotherapy clinical trial landscape is shifting, with more focused sponsorship and hopes for further innovation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-18T19:35:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/04\/MicrosoftTeams-image-9.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"876\" \/>\n\t<meta property=\"og:image:height\" content=\"493\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities\",\"url\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities\",\"name\":\"Immunotherapy Drug Development Pipeline Shifts from Traditional Therapies to Newer Modalities - Cancer Research Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/04\/MicrosoftTeams-image-9.jpg\",\"datePublished\":\"2023-04-18T19:15:24+00:00\",\"dateModified\":\"2023-04-18T19:35:24+00:00\",\"description\":\"The cancer immunotherapy clinical trial landscape is shifting, with more focused sponsorship and hopes for further innovation.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/04\/MicrosoftTeams-image-9.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/04\/MicrosoftTeams-image-9.jpg\",\"width\":876,\"height\":493},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Media Room Article\",\"item\":\"https:\/\/www.cancerresearch.org\/media-room\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Immunotherapy Drug Development Pipeline Shifts from Traditional Therapies to Newer Modalities\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunotherapy Drug Development Pipeline Shifts from Traditional Therapies to Newer Modalities - Cancer Research Institute","description":"The cancer immunotherapy clinical trial landscape is shifting, with more focused sponsorship and hopes for further innovation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities","og_locale":"es_ES","og_type":"article","og_title":"Immunotherapy Drug Development Pipeline Shifts from Traditional Therapies to Newer Modalities - Cancer Research Institute","og_description":"The cancer immunotherapy clinical trial landscape is shifting, with more focused sponsorship and hopes for further innovation.","og_url":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities","og_site_name":"Cancer Research Institute","article_modified_time":"2023-04-18T19:35:24+00:00","og_image":[{"width":876,"height":493,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/04\/MicrosoftTeams-image-9.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities","url":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities","name":"Immunotherapy Drug Development Pipeline Shifts from Traditional Therapies to Newer Modalities - Cancer Research Institute","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/04\/MicrosoftTeams-image-9.jpg","datePublished":"2023-04-18T19:15:24+00:00","dateModified":"2023-04-18T19:35:24+00:00","description":"The cancer immunotherapy clinical trial landscape is shifting, with more focused sponsorship and hopes for further innovation.","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/04\/MicrosoftTeams-image-9.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/04\/MicrosoftTeams-image-9.jpg","width":876,"height":493},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Media Room Article","item":"https:\/\/www.cancerresearch.org\/media-room"},{"@type":"ListItem","position":3,"name":"Immunotherapy Drug Development Pipeline Shifts from Traditional Therapies to Newer Modalities"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_news\/28607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_news"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/28608"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=28607"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tags?post=28607"},{"taxonomy":"resource_cancer_types","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_types?post=28607"},{"taxonomy":"resource_patient_age","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_patient_age?post=28607"},{"taxonomy":"resource_cancer_stage","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_stage?post=28607"},{"taxonomy":"resource_treatment_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_type?post=28607"},{"taxonomy":"resource_treatment_status","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_status?post=28607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}